Early miR-320b and miR-25-3p miRNA levels correlate with multiple sclerosis severity at 10 years: a cohort study

Background Multiple sclerosis (MS) is a chronic demyelinating autoimmune disorder which may cause long-term disability. MicroRNA (miRNA) are stable, non-coding molecules that have been identified in our Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women’s Hospita...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of neuroinflammation Ročník 20; číslo 1; s. 136 - 8
Hlavní autori: Gonzalez-Martinez, Alicia, Bose, Gauruv, Lokhande, Hrishikesh, Saxena, Shrishti, Healy, Brian C., Polgar-Turcsanyi, Mariann, Weiner, Howard L., Chitnis, Tanuja
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 01.06.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Adult
Alzheimer's disease
Atrophy
Benign
Biomarkers
Biomedical and Life Sciences
Biomedicine
Brain
Cohort analysis
Cohort Studies
Cytokines
Demyelination
Development and progression
Diagnosis
Disability
EDSS
Female
Health aspects
Humans
Immunology
Long-term
Male
MicroRNA
MicroRNAs
MicroRNAs - genetics
miR-25-3p
miR-320b
miRNA
Multiple sclerosis
Multiple Sclerosis - genetics
Neurobiology
Neurology
Neurosciences
Non-coding RNA
Patients
Risk factors
Statistical analysis
United States
Disability
RRMS
miR-25-3p
Multiple sclerosis
Biomarker
miR-320b
SPMS
miRNA
Long-term
EDSS
ISSN:1742-2094, 1742-2094
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background Multiple sclerosis (MS) is a chronic demyelinating autoimmune disorder which may cause long-term disability. MicroRNA (miRNA) are stable, non-coding molecules that have been identified in our Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women’s Hospital (CLIMB)-cohort, as well as other international cohorts, as potential disease biomarkers in MS. However, few studies have evaluated the association of miRNA expression early in the MS disease course with long-term outcomes. Therefore, we aimed to evaluate the potential role of three candidate serum miRNAs previously correlated with MS disability in patients with MS, miR-320b, miR-25-3p and miRNA 486-5p, as early biomarkers of MS disability at 10-year follow-up. Main body We included 144 patients with serum obtained within three years of MS onset. miRNA expression was measured by RNA extraction followed by RT-PCR. Demographic, clinical, brain MRI and other biomarkers were collected. The primary outcome was the association between early miRNA expression and retaining benign MS, defined as EDSS ≤ 2 at 10-year follow-up. Among the 144 patients, 104 were benign and 40 were not benign at 10-year follow-up. 89 (62%) were women, with mean age at onset 37.7 (SD: 9.6) years. Patients who retained benign MS had lower values of miR-25-3p ( p  = 0.047) and higher miR-320b ( p  = 0.025) values. Development of SPMS was associated with higher miR-320b ( p  = 0.002) levels. Brain parenchymal fraction at year 10 was negatively correlated with miR-25-3p ( p  = 0.0004) and positively correlated with miR-320b ( p  = 0.006). No association was found between miR-486-5p and any outcome, and 10-year T2-lesion volume was not associated with any miRNA. Conclusions Our results show that miR-320b and miR-25-3p expression are early biomarkers associated with MS severity and brain atrophy. This study provides class III evidence of that miR-320b and miR-25-3p are associated with long-term MS disability which may be a potential tool to risk-stratify patients with MS for early treatment decisions.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1742-2094
1742-2094
DOI:10.1186/s12974-023-02816-8